Zhanguo Li

2008–2026 年に発表

118
論文数
18,038
被引用数
44
h 指数
103
i10 指数

被引用数

Zhanguo Li の年別被引用数1971 年: 被引用 1 件2007 年: 被引用 1 件2008 年: 被引用 1 件2010 年: 被引用 1 件2011 年: 被引用 13 件2012 年: 被引用 35 件2013 年: 被引用 43 件2014 年: 被引用 78 件2015 年: 被引用 115 件2016 年: 被引用 122 件2017 年: 被引用 149 件2018 年: 被引用 156 件2019 年: 被引用 613 件2020 年: 被引用 813 件2021 年: 被引用 978 件2022 年: 被引用 760 件2023 年: 被引用 596 件2024 年: 被引用 951 件2025 年: 被引用 474 件2026 年: 被引用 21 件1972〜2006 年は被引用が無いため表示していません2009 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 1,379 件、この内訳の 15.1%中国: 引用元論文 1,272 件、この内訳の 14%イギリス: 引用元論文 662 件、この内訳の 7.3%ドイツ: 引用元論文 446 件、この内訳の 4.9%イタリア: 引用元論文 429 件、この内訳の 4.7%オランダ: 引用元論文 408 件、この内訳の 4.5%日本: 引用元論文 404 件、この内訳の 4.4%フランス: 引用元論文 374 件、この内訳の 4.1%オーストラリア: 引用元論文 265 件、この内訳の 2.9%カナダ: 引用元論文 252 件、この内訳の 2.8%スペイン: 引用元論文 234 件、この内訳の 2.6%スウェーデン: 引用元論文 189 件、この内訳の 2.1%
0%15.1%その他 30.6%

分野

  • Medicine66.5%
  • Immunology and Microbiology15.7%
  • Biochemistry, Genetics and Molecular Biology12.4%
  • Neuroscience1%
  • Pharmacology, Toxicology and Pharmaceutics0.7%
  • Engineering0.7%
  • その他3%

トピック

  • Rheumatoid Arthritis Research and Therapies14.8%
  • Systemic Lupus Erythematosus Research6%
  • Autoimmune and Inflammatory Disorders Research4.7%
  • Spondyloarthritis Studies and Treatments4.5%
  • T-cell and B-cell Immunology4.3%
  • Immune Cell Function and Interaction3.6%
  • その他62.1%

共著者

全論文

検索で開く
  1. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Annamaria Iagnocco, Kim Lauper, Zhanguo Li, Iain B. McInnes, Eduardo Mysler, Peter Nash, Gyula Poór, Gorica Ristić, Felice Rivellese, Andrea Rubbert‐Roth, Hendrik Schulze‐Koops, Nikolay Stoilov, Anja Strangfeld, Annette H M van der Helm–van Mil, Elsa van Duuren, T. P. M. Vliet Vlieland, René Westhovens, Désirée van der Heijde - Annals of the Rheumatic Diseases 2022 被引用: 1,788

  2. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Marios Kouloumas, Tore Kvien, Zhanguo Li, Xavier Mariette, Iain B. McInnes, Eduardo Mysler, Peter Nash, Karel Pavelká, Gyula Poór, Christophe Richez, Piet L. C. M. van Riel, Andrea Rubbert‐Roth, Kenneth G. Saag, José António Pereira da Silva, Tanja Stamm, Tsutomu Takeuchi, René Westhovens, Maarten de Wit, Désirée van der Heijde - Annals of the Rheumatic Diseases 2017 被引用: 5,775

  3. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , T. Huizinga, Marios Koloumas, Zhanguo Li, Xavier Mariette, Ulf Müller‐Ladner, Eduardo Mysler, José António Pereira da Silva, Gyula Poór, Janet Pope, Andrea Rubbert‐Roth, Adeline Ruyssen‐Witrand, Kenneth G. Saag, Anja Strangfeld, Tsutomu Takeuchi, Marieke Voshaar, René Westhovens, Désirée van der Heijde - Annals of the Rheumatic Diseases 2020 被引用: 2,766

  4. Intestinal butyrate-metabolizing species contribute to autoantibody production and bone erosion in rheumatoid arthritis

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Science Advances 2022 被引用: 222

  5. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Zhanguo Li - Annals of the Rheumatic Diseases 2019 被引用: 337

  6. Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Di Yu, Zhanguo Li - Nature Medicine 2016 被引用: 572

  7. Circulating Precursor CCR7loPD-1hi CXCR5+ CD4+ T Cells Indicate Tfh Cell Activity and Promote Antibody Responses upon Antigen Reexposure

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Immunity 2013 被引用: 654

  8. Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michael Tee, Naoaki Ohkubo, Yoshiya Tanaka, DaeYoung Yu, Chetan S. Karyekar, Chak Sing Lau, Julie A. Monk, Mandana Nikpour, Alberta Hoi, Eric F. Morand - The Lancet Rheumatology 2022 被引用: 67

  9. A missense variant in NCF1 is associated with susceptibility to multiple autoimmune diseases

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Nature Genetics 2017 被引用: 182

  10. Targeting TFH cells in human diseases and vaccination: rationale and practice

    著者: , , , , - Nature Immunology 2022 被引用: 135

  11. Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jianping Guo, Wanli Liu, Wenbin Zhang, Alexander Jacob, Julian L. Ambrus, Changhai Ding, Di Yu, Xiaolin Sun, Zhanguo Li - JAMA Network Open 2022 被引用: 88

  12. Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis

    著者: , , , , , , , , , , , , , - Annals of Internal Medicine 2013 被引用: 447

  13. Myricetin possesses the potency against SARS-CoV-2 infection through blocking viral-entry facilitators and suppressing inflammation in rats and mice

    著者: , , , , , , , , , , , , , , , , - Phytomedicine 2023 被引用: 36

  14. 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis

    著者: , , , , , , , , , , , , , , , , , , , - International Journal of Rheumatic Diseases 2019 被引用: 176

  15. Double-negative (DN) B cells: an under-recognized effector memory B cell subset in autoimmunity

    著者: , , - Clinical & Experimental Immunology 2021 被引用: 106

  16. Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Signal Transduction and Targeted Therapy 2022 被引用: 69

  17. Genetic association of PRDM1-ATG5 intergenic region and autophagy with systemic lupus erythematosus in a Chinese population

    著者: , , , , , , , , - Annals of the Rheumatic Diseases 2011 被引用: 235

  18. An Asia-specific variant of human IgG1 represses colorectal tumorigenesis by shaping the tumor microenvironment

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Lei Zhang, Zhanlong Shen, Wanli Liu - Journal of Clinical Investigation 2022 被引用: 44

  19. Myeloid-derived suppressor cells have a proinflammatory role in the pathogenesis of autoimmune arthritis

    著者: , , , , , , , , , , , , - Annals of the Rheumatic Diseases 2014 被引用: 160

  20. Hypoxia‐inducible factor‐1α perpetuates synovial fibroblast interactions with T cells and B cells in rheumatoid arthritis

    著者: , , , , , , , , , , , - European Journal of Immunology 2015 被引用: 90

  21. Dilemma of immunosuppression and infection risk in systemic lupus erythematosus

    著者: , - Lara D. Veeken 2023 被引用: 50

  22. LAG3 (CD223) and autoimmunity: Emerging evidence

    著者: , , , , - Journal of Autoimmunity 2020 被引用: 50

  23. The metabolic hormone leptin promotes the function of TFH cells and supports vaccine responses

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Lilin Ye, Steven Rockman, Michelle A. Linterman, Katherine Kedzierska, Nan Shen, Liwei Lu, Di Yu - Nature Communications 2021 被引用: 42

  24. Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michael Tee, Naoaki Ohkubo, Yoshiya Tanaka, Sandra Navarra, Chak Sing Lau, Alberta Hoi, Eric F. Morand, Mandana Nikpour, Aisha Lateef - The Lancet Rheumatology 2023 被引用: 28